SMMT Share Price Performance

US$16.90

-2.20 (-11.52%)

US$41.04

Fair Value

US$16.90

-2.20 (-11.52%)

58.8% undervalued

US$41.04

Fair Value

US$16.90

US$41.04

US$29.21

US$11.08

Fri, 7 Aug 26

Fair ValueUS$41.04

Share Pricen/a

SMMT Community Narratives

AnalystHighTarget's

Fair Value

Fair Value US$41.04 58.8% undervalued

Late Stage Oncology Footprint Will Transform This Single Asset Into A Global Cancer Franchise

AnalystConsensusTarget's

Fair Value

Fair Value US$29.21 42.1% undervalued

Broad Late‑Stage Immuno Oncology Pipeline Will Drive Long Term Opportunity

AnalystLowTarget's

Fair Value

Fair Value US$11.08 52.6% overvalued

Future Clinical Setbacks In Phase III Programs Will Threaten Long Term Oncology Ambitions

About SMMT

Founded: 2003
Employees: 265
CEO: Robert Duggan
WebsiteView website: www.smmttx.com

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth factor receptor, mutated, and locally advanced or metastatic non-squamous NSCLC; first-line metastatic NSCLC; and first-line unresectable metastatic CRC. It markets its products in the United states, Canada, Europe, Japan, Latin America, Middle East, and Africa. The company was founded in 2003 and is headquartered in Miami, Florida.

Recent SMMT News & Updates

Announcement • 7h

Akeso, Inc. and Summit Therapeutics Inc. Showcase HARMONi-G11 Phase III Trial Data Featuring Ivonescimab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer At ESMO 2026

Summit Therapeutics Inc. noted that data from the Phase III HARMONi-GI1 trial, conducted in China and sponsored by Akeso, Inc., featuring the novel, potential first-in-class investigational bispecific antibody ivonescimab, will be featured as part of the Presidential Symposium II at the European Society for Medical Oncology 2026 Congress (ESMO 2026) which takes place October 23–27, 2026, in Madrid, Spain. The presentation will take place on Sunday, October 25 during the Presidential Symposium from 4:30pm – 6:15pm CET (11:30am – 1:15pm EDT). The HARMONi-GI1 study is evaluating ivonescimab plus chemotherapy compared with durvalumab plus chemotherapy as a first-line treatment for patients with advanced biliary tract cancer (BTC). HARMONi-GI1 is a single-region, multi-center, Phase III study conducted in China and sponsored by Akeso, with all relevant data exclusively generated, managed, and analyzed by Akeso. On August 25, 2026, Akeso announced topline results from HARMONi-GI1. Akeso reported that, at a pre-specified interim analysis, the ivonescimab-based regimen achieved statistically significant and clinically meaningful superiority in the primary endpoint of overall survival (OS) compared to the durvalumab-based regimen. The study also met the key secondary endpoints of progression-free survival (PFS) and objective response rate (ORR). Presentation Title: Ivonescimab plus chemotherapy versus durvalumab plus chemotherapy as first-line treatment for advanced biliary tract cancer: a randomized, controlled, double-blinded, phase 3 trial (HARMONi-GI1) ESMO Presentation No.: Presidential Symposium II, LBA8 Session Date & Time: Sunday, October 25, 2026, 4:30pm – 6:15pm CET (11:30am – 1:15pm EDT) In China, ivonescimab is approved and commercially available for indications in non-small cell lung cancer (NSCLC). Ivonescimab remains investigational and is not approved by any regulatory authority in Summit’s license territories, including the United States and Europe. Ivonescimab, known as SMT112 in Summit’s license territories, North America, South America, Europe, the Middle East, Africa, and Japan, and as AK112 outside of Summit’s license territories, is a novel, potential first-in-class investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. By design, ivonescimab displays unique cooperative binding to each of its intended targets with multifold higher affinity to PD-1 when in the presence of VEGF. Ivonescimab was engineered by Akeso Inc. (HKEX Code: 9926.HK) and is currently utilized in multiple Phase III clinical trials. Over 5,000 patients have been treated with ivonescimab in clinical studies globally and over 100,000 patients when considering those treated in a commercial setting in China, as noted by Akeso. There are currently 16 Phase III clinical studies that are either announced, ongoing, or have been completed studying ivonescimab, five of which are Summit-sponsored global studies, one of which is a multiregional study sponsored by a cooperative group, and 10 of which are being or have been conducted in China by Akeso.

Recent updates

No updates

Summit Therapeutics Inc. Stock Price

SMMT Share Price Performance

SMMT Community Narratives

Late Stage Oncology Footprint Will Transform This Single Asset Into A Global Cancer Franchise

Broad Late‑Stage Immuno Oncology Pipeline Will Drive Long Term Opportunity

Future Clinical Setbacks In Phase III Programs Will Threaten Long Term Oncology Ambitions

Broad Late‑Stage Immuno Oncology Pipeline Will Drive Long Term Opportunity

Future Clinical Setbacks In Phase III Programs Will Threaten Long Term Oncology Ambitions

Late Stage Oncology Footprint Will Transform This Single Asset Into A Global Cancer Franchise

Trending Discussion

Recently Updated Narratives

SMMT: Upcoming HARMONi-3 PFS Readout Will Drive Repricing Potential

SMMT: Extended Survival Timelines And Dilution Risk Will Likely Pressure Shares

SMMT: HARMONi Survival Readouts And FDA Decision Will Drive Future Repricing

Snowflake Analysis

Summit Therapeutics Inc. Key Details

About SMMT

Recent SMMT News & Updates

Akeso, Inc. and Summit Therapeutics Inc. Showcase HARMONi-G11 Phase III Trial Data Featuring Ivonescimab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer At ESMO 2026

Summit Therapeutics: It's Okay Not To Have An Answer

Summit Therapeutics Reports Survival Benefit in Ivonescimab Phase III Lung Cancer Trial

Recent updates

Summit Therapeutics Inc. Competitors

Regeneron Pharmaceuticals

Moderna

Natera

Teva Pharmaceutical Industries